Mon-03-08-2020, 18:41 PM
Update:
Cosentyx (secukinumab)
Quote:
Novartis have announced the European Commission (EC) has granted the approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to 18 years.
The recommended dose for children up to 50 kg is 75 mg (without a lower weight restriction), and 150 mg for children 50 kg and over (150 mg as a starting dose, which may be increased to 300 mg, if needed).
Cosentyx (secukinumab)